Erythropoietin—Not Yet a Standard Treatment for Anemia of Prematurity

摘要: In this issue of Pediatrics , Shannon and coworkers report that the frequency volume red cell transfusions administered to premature infants can be decreased by using recombinant human erythropoietin (r-HuEPO). We believe most important contribution study may relate as much its design—that is, application clearly defined transfusion guidelines—as efficacy r-HuEPO in setting. In randomized, controlled multicenter trial, 157 weighing <1250 g at birth received either or placebo. These (mean age = 24 days) had an average 3.5 before their enrollment. During study, packed blood were given according criteria developed investigators.